best glp-1 drug 2025 How Employers Can Manage Costs in Their Health Plans GLP-1 Pipeline Update: May 2025
Description
The RR for the occurrence of respiratory disease in patients receiving Efpeglenatide was 0.76 (95% CI 0.461.24, p = 0.27)
Stanghellini V, Tosetti C, Paternico A, et al
However, observational studies have identified potential risk-amplifying effects in specific clinical contexts
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
in fact, some clinical evidences suggest it may have a potential protective effect in reducing lung cancer risk
This suggests a direct effect on the adaptive immune response driving MS
